<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525172</url>
  </required_header>
  <id_info>
    <org_study_id>201504036MIPB</org_study_id>
    <nct_id>NCT02525172</nct_id>
  </id_info>
  <brief_title>Immune Modulation Therapy for Pompe Disease</brief_title>
  <official_title>Immune Modulation Therapy for ERT-naïve or ERT-treated Pompe Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess anti-recombinant human acid α-glucosidase (anti-rhGAA)
      antibody titers after treatment with immune modulation therapy in patients of Pompe disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti-recombinant human acid α-glucosidase (anti-rhGAA) antibody titers decrease</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Pompe Disease</condition>
  <arm_group>
    <arm_group_label>ITT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immune modulation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <arm_group_label>ITT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous immune globulin</intervention_name>
    <arm_group_label>ITT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <arm_group_label>ITT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>ITT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient (and/or patient's legal guardian if patient is &lt; 18years) must provide
             written informed consent prior to any study-related procedures that are performed;

          -  The patient must have a confirmed diagnosis of Pompe disease defined as a documented
             acid α-glucosidase (GAA) enzyme deficiency from blood samples or 2 GAA gene mutations;

          -  The patient (and/or legal guardian) must have ability to comply with clinical
             protocol;

          -  Regimen A only: The patient is receiving enzyme replacement therapy, exhibits clinical
             decline, and has persistent high anti-recombinant human acid α-glucosidase
             (anti-rhGAA) antibody titers and/or tested positive for antibodies that inhibit
             enzymatic activity and/or uptake of Myozyme;

          -  Regimen B only: The patient is cross-reactive immune material (CRIM) -negative AND
             have not received Myozyme infusion prior to enrollment

        Exclusion Criteria:

          -  The patient is at risk of reactivation or is a carrier of Hepatitis B or Hepatitis C;

          -  The patient is at risk of reactivation of tuberculosis or has regular contact with
             individuals who are being actively treated for tuberculosis;

          -  The patient has used any investigational product (other than alglucosidase alfa)
             within 30 days prior to study enrollment;

          -  The patient is pregnant or lactating;

          -  The patient has had or is required to have any live vaccination within one month prior
             to enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yin-Hsiu Chien</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yin-Hsiu Chien</last_name>
    <phone>+886223123456</phone>
    <email>chienyh@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yin-Hsiu Chien</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yin-Hsiu Chien</last_name>
      <phone>+886223123456</phone>
      <email>chienyh@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Yin-Hsiu Chien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <last_update_submitted>April 13, 2016</last_update_submitted>
  <last_update_submitted_qc>April 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immune modulation therapy</keyword>
  <keyword>acid α-glucosidase</keyword>
  <keyword>antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

